Bionano Genomics Sees OGM Adoption Accelerate Amid Genomics Data Sharing
Event summary
- Bionano Genomics reported a two-fold increase in Optical Genome Mapping (OGM) studies presented at the 2026 ACMG Annual Meeting, totaling twelve presentations.
- Four presentations were oral, and eight were poster presentations, covering applications in cancer genomics, rare diseases, and reproductive disorders.
- Greenwood Genetic Center hosted an 'Ask the OGM Expert' workshop, and Baylor Genetics launched a commercial service providing OGM data to the research community.
- The presentations highlighted OGM's ability to detect structural variants often missed by other genomic analysis techniques.
The big picture
Bionano's announcement signals a potential shift towards more comprehensive genomic analysis, particularly in areas like rare disease diagnosis and cancer research where structural variant detection is crucial. The increased adoption of OGM, coupled with the data sharing initiative from Baylor Genetics, suggests a move towards greater collaboration and data accessibility within the genomics research community. However, the company's success hinges on demonstrating consistent clinical utility and securing reimbursement for its OGM services, a challenge given the competitive landscape of genomic sequencing.
What we're watching
- Adoption Rate
- The pace at which broader adoption of OGM services by clinical labs and research institutions will validate the commercial viability of Baylor Genetics’ new data sharing service.
- Competitive Landscape
- How the increased visibility of OGM’s capabilities will affect the competitive dynamics with existing short-read and long-read sequencing technologies.
- Clinical Validation
- Whether the real-world evidence presented at ACMG will translate into increased clinical utility and reimbursement for OGM-based diagnostic testing.
Related topics